Schrödinger plans to meet with the FDA to discuss the Phase 2 dose of a drug.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Schrödinger plans to meet with the FDA to discuss the Phase 2 dose of a drug.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Schrödinger
American life sciences company
Nothing else this week.
- FDA
Related events
- SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
Coverage
Newest first; wire copies grouped- Business WireSchrödinger Reports Second Quarter 2025 Financial Results Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers